Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

More research is needed to improve the treatment of brain diseases such as depression, Alzheimer’s or ADHD. A widely held view within the scientific community is that this cannot be done without ethically conducted animal research. A team of seventy international neuroscientists, including DPAG’s Associate Professor Vladyslav Vyazovskiy, have now published a warning that animal research is under pressure, which endangers the further development of treatments.

Over one third of Europeans, some 170 million people, suffer from brain disorders such as ADHD, autism, Parkinson's, Alzheimer's, anxiety disorders and brain tumors. Many of these diseases have a major impact on patients and their families, are not yet curable and have high social costs.

We still know relatively little about the functioning of the brain. As a result, brain diseases are often difficult to treat. Neuroscientists study the entire spectrum of the brain: from molecules and cells to brain regions and from their mutual interactions to ultimately behavior and cognition. Researchers use a variety of research methods to do this, including animal studies, which are subject to rigorous ethnical guidelines. However, this research is increasingly under pressure, which seventy neuroscientists from around the world, including University of Oxford researchers Associate Professor Vladyslav Vyazovskiy (DPAG) and Associate Professor Anna Mitchell (Experimental Psychology), warn about in scientific journal Neuron. In a new paper published yesterday, researchers argue that the development of new treatments for brain disorders is at risk.

You can’t know what you don’t know

Because so little is still known about the construction and functioning of the brain, little is known about how brain disorders arise and how they can be treated. Therefore, neuroscientists often don't know how their research will go and what outcome they can expect. However, in an application for scientific research, advance knowledge of the likely outcome is usually expected. Current regulations allow for research applications to be made for a period of five years. Such an application requires many details about the expected course of the study and the exact design of the experiments. Any deviation from the original application requires new permission. “As a result, the quality of research suffers: sometimes there is too little time left to conduct experiments or new scientific insights cannot be incorporated into an experiment. This has consequences for the quality: a researcher is not always able to follow a new line of reasoning based on the results obtained. And that is precisely when the greatest discoveries are made.” – Homberg et al.

Slowdown or standstill

The researchers argue that the application system has become too inflexible to make the best choices during experiments, which impacts the knowledge they acquire during the research. Experimental animal research is accompanied by strict regulations to ensure animal welfare, but the associated increasing administrative burden can cause studies to be delayed or even halted, and prevent the implementation of new, more refined procedures and techniques. “In the long run, this could lead to no further progress in neuroscience research, which would prevent us as a society from moving closer to possible treatments. We also fear the risk that animal research will move to countries where animal welfare standards differ from the high standards set by the European Union. With our new publication, we call for monitoring of the long-term consequences of these increasing administrative restrictions on scientific research.” – Homberg et al.

Alternatives to laboratory animals

Brain research also uses research methods other than just animal testing. As many other European countries, the United Kingdom pursues the 3Rs (replacement, reduction and refinement of laboratory animals), aiming to lead the way in animal-free innovations, such as cultured mini-organs. Mini-organs, made from human cells, offer the possibility of answering specific research questions and can be complementary to animal research. “But brain diseases are disorders that affect interaction with the environment and alter behaviour. A mini-brain will never be able to respond to the environment and cannot exhibit behavior and cognition. Computer systems can also support, but not replace, laboratory animal research. Little is yet known about the brain to build a computer system that can reliably mimic the brain. This makes brain research a field where animal-free research is far from always possible.” – Homberg et al.

Science in brain disorders

Neuroscientists conduct research on how the brain works and why some people get sick and others do not. They also work with doctors to try to understand why some people do not respond to medication, or respond very poorly. “This cannot be done without animal studies, because these provide information about the underlying workings of the brain: what happens in the brain when a certain treatment is applied? This is necessary to determine which cells and substances are involved in responses to drugs. This type of research thus contributes significantly to the knowledge of brain diseases, such as ADHD, autism, anxiety disorders, depression, eating disorders, Alzheimer's, Parkinson's, epilepsy, ALS and brain tumors: diseases that can hardly be prevented, but which, with new and improved treatment methods, we can do more and more about.” – Homberg et al.

 

DPAG’s Associate Professor Vladyslav Vyazovskiy is keen to emphasise that for neuroscientists like himself, animal welfare and the ethics of animal experimentation are of the highest priority: “We do not simply follow the best standards, we set new higher standards that improve the welfare of laboratory animals.  My research area - sleep - is an excellent example where it is impossible to obtain meaningful data unless animals are happy, healthy, maintained in the most optimal conditions, and taken good care of. Only ethical animal research can advance brain sciences and we are committed to adhering to that.”

 

The full paper “The continued need for animals to advance brain research” is available to read in Neuron.

This text is adapted from a press release written by Pauline Dekhuijzen, Roeland Segeren, Judith Homberg, Monique Wolvekamp and Lisa Genzel.

Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.

Vladyslav Vyazovskiy reflects on the Braemar Summit 2022

Professor of Sleep Physiology Vladyslav Vyazovskiy was invited to attend the Braemar Summit 2022, a prestigious annual conference attended by around 100 participants, showcasing the best that is being said and thought in the UK.